丹参联合美沙拉嗪治疗溃疡性结肠炎的系统评价与Meta分析
该研究通过系统评价与Meta分析,纳入37项研究(26项临床试验含2426例患者、11项动物实验含208只动物),评估丹参制剂联合美沙拉嗪治疗溃疡性结肠炎的疗效与安全性。结果显示,联合用药可提高临床有效率,改善凝血功能并降低炎症因子水平,但研究存在分配隐藏和盲法缺陷,需谨慎解读。
要点
- 丹参制剂联合美沙拉嗪可提高溃疡性结肠炎临床有效率(RR 0.86,95% CI 0.83-0.88,p<0.00001)。
- 联合治疗可降低血清PLT、升高MPV,改善凝血功能。
- 联合治疗可降低血清CRP、TNF-α、IL-6、IL-8水平,控制炎症反应。
核心结论
- 丹参制剂联合美沙拉嗪治疗溃疡性结肠炎可增强临床疗效,但受分配隐藏和盲法不确定性等缺陷影响,结果需谨慎解读。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Cochrane Library、Web of Science、CNKI、万方和维普数据库。
- 共纳入37项研究,其中26项临床试验涉及2426例患者,11项动物实验涉及208只动物。
- 使用Cochrane偏倚风险工具评估偏倚风险,采用RevMan5.4和Stata17.0软件进行质量评价和数据处理。
主要发现
- 与单用美沙拉嗪相比,联合丹参制剂可明显提高溃疡性结肠炎临床有效率(RR 0.86,95% CI:0.83-0.88,p<0.00001)。
- 联合治疗通过降低血清PLT和升高MPV改善凝血功能。
- 联合治疗通过降低血清CRP、TNF-α、IL-6和IL-8水平控制炎症反应。
临床怎么用
- 在临床中可考虑丹参制剂联合美沙拉嗪用于溃疡性结肠炎,以提升疗效并改善凝血和炎症指标。
- 需注意现有证据存在方法学缺陷,应用时应结合患者具体情况谨慎决策。
局限性
- 纳入研究存在分配隐藏和盲法不确定性等缺陷,可能影响结果可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose: Current pharmacological treatments for Ulcerative Colitis (UC) have limitations. Therefore, it is important to elucidate any available alternative or complementary treatment, and Chinese herbal medicine shows the potential for such treatment. As a traditional Chinese herbal medicine, Danshen-related preparations have been reported to be beneficial for UC by improving coagulation function and inhibiting inflammatory responses. In spite of this, the credibility and safety of this practice are incomplete. Therefore, in order to investigate whether Danshen preparation (DSP) is effective and safe in the treatment of UC, we conducted a systematic review and meta-analysis. Methods: PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang Database and CQVIP Database were searched for this review.The main observation indexes were the effect of DSP combined with mesalazine or DSP on the effective rate, platelet count (PLT), mean platelet volume (MPV) and C-reactive protein (CRP) of UC. The Cochrane risk of bias tool was used to assess the risk of bias. The selected studies were evaluated for quality and data processing using RevMan5.4 and Stata17.0 software. Results: A total of 37 studies were included. Among them, 26 clinical trials with 2426 patients were included and 11 animal experimental studies involving 208 animals were included. Meta-analysis results showed that compared with mesalazine alone, combined use of DSP can clearly improve the clinical effective rate (RR 0.86%, 95% CI:0.83-0.88, p < 0.00001) of UC. Furthermore it improved blood coagulation function by decreasing serum PLT and increasing MPV levels, and controlled inflammatory responses by reducing serum CRP, TNF-α, IL-6, and IL-8 levels in patients. Conclusion: Combining DSP with mesalazine for UC can enhance clinical efficacy. However, caution should be exercised in interpreting the results of this review due to its flaws, such as allocation concealment and uncertainty resulting from the blinding of the study. Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/myprospero.php, identifier PROSPERO: CRD42022293287.
引用
- Zhang W, Xiong P, Liu J, et al. A systematic review and meta-analysis of Danshen combined with mesalazine for the treatment of ulcerative colitis. Front Pharmacol. 2024. PMID: 38881869. doi:10.3389/fphar.2024.1334474
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。